AIM: To observe the changes of retinal structure in macular region of wet age-related macular degeneration(wARMD)after treatment with conbercept by optical coherence tomography(OCT), and explore the effect of conbercept on wARMD.

METHODS: From May 2018 to October 2018, 21 patients(23 eyes)with wARMD were studied. All patients were treated by intravitreal injection of conbercept monthly for 3mo. During the six-month follow-up period after the last injection, the changes of best corrected visual acuity(BCVA)and intraocular pressure were observed, in the meantime, the macular fovea retinal thickness(CFT), macular fovea pararetinal thickness(PMT), choroidal neovascularization(CNV)area and subretinal fibrosis also were observed by OCT.

RESULTS:Six months after treatment, 21 eyes(91%)was effective, and 2 eyes(9%)was stable in all patients. 1mo, 3mo and 6mo after treatment, the BCVA of patients were significantly improved, the areas of CFT, PMT and CNV decreased significantly compared with those of before(P<0.05), while intraocular pressure did not change significantly before and after treatment(P>0.05). During the follow-up period, transient blurred vision occurred in 2 eyes(9%), intraocular pressure increased(>21mmHg)in 1 eye(4%)and subconjunctival hemorrhage in 1 eye(4%)of 23 eyes, and all recovered within 7d after the end of 3 conbercept treatments.

CONCLUSION: The application of conbercept in the treatment of wARMD can significantly improve the patients' vision and retinal structure in macular region. And it also shows good therapeutic effect, less side effects and high safety.